Stem cell shot aims to tame multiple sclerosis

NCT ID NCT04956744

Ongoing Disease control Sponsor: ImStem Biotechnology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a single intravenous dose of IMS001, a stem cell product made from human embryonic cells, in 30 adults with multiple sclerosis who have not responded well to standard treatments. The main goal is to see if the treatment is safe and tolerable, while also looking for any signs that it might help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IMS001 (stem cells from human embryos)
What this could lead to: If it works, this could point toward a new treatment option for multiple sclerosis patients who haven't responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 30 people, so it's mainly checking safety. The stem cells may not improve symptoms, and there could be side effects like allergic reactions or lab abnormalities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Rocky Mountain MS Clinic

Salt Lake City, Utah, 84103, United States
Shepherd Center

Atlanta, Georgia, 30309, United States
UMass Memorial Medical Center

Worcester, Massachusetts, 01605, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.